Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Payables (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Payables for 15 consecutive years, with $20.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 97.85% to $20.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.6 million through Dec 2025, up 97.85% year-over-year, with the annual reading at $20.6 million for FY2025, 97.85% up from the prior year.
  • Payables hit $20.6 million in Q4 2025 for Perspective Therapeutics, up from $13.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $21.9 million in Q3 2024 to a low of $98000.0 in Q2 2021.
  • Historically, Payables has averaged $6.1 million across 5 years, with a median of $5.0 million in 2023.
  • Biggest five-year swings in Payables: tumbled 87.4% in 2022 and later skyrocketed 4352.0% in 2023.
  • Year by year, Payables stood at $153000.0 in 2021, then soared by 907.19% to $1.5 million in 2022, then surged by 351.52% to $7.0 million in 2023, then surged by 49.4% to $10.4 million in 2024, then soared by 97.85% to $20.6 million in 2025.
  • Business Quant data shows Payables for CATX at $20.6 million in Q4 2025, $13.2 million in Q3 2025, and $7.1 million in Q2 2025.